Details for Patent: RE48059
✉ Email this page to a colleague
Which drugs does patent RE48059 protect, and when does it expire?
Patent RE48059 protects REXULTI and is included in one NDA.
Protection for REXULTI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-five patent family members in twenty-nine countries.
Summary for Patent: RE48059
| Title: | Piperazine-substituted benzothiophenes for treatment of mental disorders |
| Abstract: | The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. ##STR00001## |
| Inventor(s): | Yamashita; Hiroshi (Tokushima, JP), Ito; Nobuaki (Tokushima, JP), Miyamura; Shin (Tokushima, JP), Oshima; Kunio (Tokushima, JP), Matsubara; Jun (Tokushima, JP), Kuroda; Hideaki (Tokushima, JP), Takahashi; Haruka (Tokushima, JP), Shimizu; Satoshi (Tokushima, JP), Tanaka; Tatsuyoshi (Tokushima, JP), Oshiro; Yasuo (Tokushima, JP), Taira; Shinichi (Tokushima, JP) |
| Assignee: | Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) |
| Application Number: | 15/815,650 |
|
Patent Claim Types: see list of patent claims | Compound; Process; |
More… ↓ |
Drugs Protected by US Patent RE48059
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-001 | Jul 10, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-002 | Jul 10, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-003 | Jul 10, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-004 | Jul 10, 2015 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-005 | Jul 10, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-006 | Jul 10, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: RE48059
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2005-116698 | Apr 14, 2005 |
| PCT Information | |||
| PCT Filed | April 12, 2006 | PCT Application Number: | PCT/JP2006/308162 |
| PCT Publication Date: | October 26, 2006 | PCT Publication Number: | WO2006/112464 |
International Family Members for US Patent RE48059
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1869025 | ⤷ Subscribe | 300946 | Netherlands | ⤷ Subscribe |
| European Patent Office | 1869025 | ⤷ Subscribe | 122018000088 | Germany | ⤷ Subscribe |
| European Patent Office | 1869025 | ⤷ Subscribe | PA2018509 | Lithuania | ⤷ Subscribe |
| European Patent Office | 1869025 | ⤷ Subscribe | CA 2018 00028 | Denmark | ⤷ Subscribe |
| European Patent Office | 1869025 | ⤷ Subscribe | LUC00086 | Luxembourg | ⤷ Subscribe |
| European Patent Office | 1869025 | ⤷ Subscribe | 32/2018 | Austria | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
